Suppr超能文献

接受磁共振成像引导聚焦超声(MRgFUS)治疗子宫肌瘤的女性的长期结局和再次干预率:一项7年随访研究。

Long-term outcomes and re-intervention rates in women undergoing mri-guided focused ultrasound (mrgfus) for uterine fibroids: a 7-year follow-up study.

作者信息

Inbar Yael, Rabinovici Jaron, Sverdlove Rachael, Ziv-Baran Tomer, Machtinger Ronit

机构信息

Department of Diagnostic Imaging, Sheba Medical Center, Ramat-Gan, Israel.

Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.

出版信息

J Assist Reprod Genet. 2025 Apr;42(4):1191-1196. doi: 10.1007/s10815-025-03405-9. Epub 2025 Feb 3.

Abstract

PURPOSE

To assess the long-term outcomes of MR-guided focused ultrasound (MRgFUS) for treating uterine fibroids, focusing on re-intervention rates, pregnancy outcomes, and the onset of menopause over a 7-year follow-up period.

MATERIALS AND METHODS

We conducted a historical cohort study of 99 women with symptomatic uterine fibroids who underwent MRgFUS between 2013 and 2020 at a single tertiary medical center. Data collection included patient demographics, treatment details, and follow-up interviews. Re-intervention rates were evaluated using Kaplan-Meier curves and Cox regression analysis to identify predictors of further treatments, with a specific focus on age-related differences.

RESULTS

Over a median follow-up of 6.1 years, 33.1% of women required re-intervention for persistent fibroid symptoms. The median patient's age was 43 years old. Women aged ≤ 43 years had significantly higher re-intervention rates than those aged 44 + years (47.5% vs. 16.7%, p = 0.005). Multivariable Cox regression identified age as the sole significant predictor of re-intervention (HR 0.303 95% CI 0.128-0.714, p = 0.006). Sixteen women conceived after MRgFUS, resulting in 21 pregnancies, with 72.2% live births and a spontaneous miscarriage rate of 22.2%. The mean age of menopause was 51.4 years, similar to global averages.

CONCLUSIONS

MRgFUS is a practical, noninvasive option for treating symptomatic uterine fibroids. Older women show lower re-intervention rates. Pregnancies post-MRgFUS are possible, and the procedure does not appear to affect the onset of menopause. Age remains a crucial predictor for further re-intervention.

摘要

目的

评估磁共振引导聚焦超声(MRgFUS)治疗子宫肌瘤的长期疗效,重点关注7年随访期内的再次干预率、妊娠结局和绝经情况。

材料与方法

我们对99例有症状的子宫肌瘤女性患者进行了一项历史性队列研究,这些患者于2013年至2020年在一家三级医疗中心接受了MRgFUS治疗。数据收集包括患者人口统计学资料、治疗细节和随访访谈。使用Kaplan-Meier曲线和Cox回归分析评估再次干预率,以确定进一步治疗的预测因素,特别关注年龄相关差异。

结果

中位随访6.1年,33.1%的女性因肌瘤持续症状需要再次干预。患者中位年龄为43岁。年龄≤43岁的女性再次干预率显著高于44岁及以上的女性(47.5%对16.7%,p = 0.005)。多变量Cox回归分析确定年龄是再次干预的唯一显著预测因素(风险比0.303,95%置信区间0.128 - 0.714,p = 0.006)。16名女性在MRgFUS治疗后怀孕,共21次妊娠,活产率为72.2%,自然流产率为22.2%。绝经平均年龄为51.4岁,与全球平均水平相似。

结论

MRgFUS是治疗有症状子宫肌瘤的一种实用、无创的选择。年龄较大的女性再次干预率较低。MRgFUS治疗后可以怀孕,且该手术似乎不影响绝经。年龄仍然是进一步再次干预的关键预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7af/12055703/cbec953a2fa0/10815_2025_3405_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验